Capsida Biotherapeutics

Apr 03, 2025

Capsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson's Disease Associated with GBA Mutations (PD-GBA)

Dec 06, 2024

New Preclinical Data Demonstrate Potential of Capsida's IV Gene Therapy for STXBP1-DEE to Correct all Disease Manifestations

Nov 12, 2024

Capsida Biotherapeutics to Present New Preclinical Data for Potential Best-in-Class Friedreich's Ataxia Next-Generation Gene Therapy

Oct 30, 2024

FDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic Encephalopathy

Sep 04, 2024

Capsida Biotherapeutics to Participate in Upcoming Investor and Industry Conferences Highlighting Progress With its Wholly Owned Programs in IND-enabling Studies

May 07, 2024

Capsida Biotherapeutics Presents New Preclinical Evidence Indicating Novel First-in-Class IV-Administered Gene Therapy Effectively Treats Genetic Epilepsy Due to STXBP1 Mutations

Apr 22, 2024

Capsida Biotherapeutics to Present New Data on its Wholly Owned Gene Therapy Programs in Genetic Epilepsy and Parkinson's Disease at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Mar 12, 2024

Capsida Biotherapeutics Announces Promotion of Rob Murphy to Chief Manufacturing and Quality Officer

Feb 21, 2024

Capsida Biotherapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference